Get the Stockscreener App
37.85
4.44%
-1.76
Pre-market:
37.68
-0.17
-0.45%
Arrowhead Pharmaceuticals Inc stock is traded at $37.85, with a volume of 1.99M.
It is down -4.44% in the last 24 hours and up +4.79% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$39.61
Open:
$38.6
24h Volume:
1.99M
Relative Volume:
0.85
Market Cap:
$5.23B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-27.23
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
-4.30%
1M Performance:
+4.79%
6M Performance:
+162.48%
1Y Performance:
+88.68%
1-Day Range:
$37.77
$39.31
1-Week Range:
$37.77
$43.69
52-Week Range:
$9.57
$43.69
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
37.85 | 5.48B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Bryce Point Capital LLC Invests $164,000 in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How to escape a deep drawdown in Arrowhead Pharmaceuticals Inc.Watch List & Verified Momentum Stock Alerts - newser.com
Best data tools to analyze Arrowhead Pharmaceuticals Inc. stock2025 Risk Factors & Low Drawdown Momentum Ideas - newser.com
How Arrowhead Pharmaceuticals Inc. (HDP1) stock behaves under inflation pressureWeekly Trend Report & Capital Efficiency Focused Strategies - newser.com
Will Arrowhead Pharmaceuticals Inc. stock split again soonEarnings Miss & Advanced Swing Trade Entry Alerts - newser.com
Risk vs reward if holding onto Arrowhead Pharmaceuticals Inc.Stock Surge & AI Based Buy and Sell Signals - newser.com
Is Arrowhead Pharmaceuticals Inc. stock attractive for growth ETFsInsider Buying & AI Enhanced Trading Signals - newser.com
How sentiment analysis helps forecast Arrowhead Pharmaceuticals Inc.July 2025 PostEarnings & Fast Entry Momentum Trade Alerts - newser.com
Privium Fund Management Sells Into Strength in Pharma Stock - The Globe and Mail
How Arrowhead Pharmaceuticals Inc. (ARWR) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why Arrowhead Pharmaceuticals Inc. is moving todayQuarterly Profit Summary & Short-Term Trading Alerts - newser.com
Can Arrowhead Pharmaceuticals Inc. stock sustain revenue growth2025 Market Sentiment & Weekly Watchlist for Hot Stocks - newser.com
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences - Business Wire
Will Arrowhead Pharmaceuticals Inc. stock gain from lower inflationQuarterly Earnings Summary & AI Powered Buy and Sell Recommendations - newser.com
Advanced analytics toolkit walkthrough for Arrowhead Pharmaceuticals Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com
Trend analysis for Arrowhead Pharmaceuticals Inc. this week2025 Analyst Calls & Momentum Based Trading Signals - newser.com
Will Arrowhead Pharmaceuticals Inc. stock continue dividend increasesWeekly Stock Report & Smart Swing Trading Techniques - newser.com
Hypertriglyceridemia: Clinical Landscape, Companies, Therapeutic Assessment, Treatment Algorithm, and Pipeline Insights | Key Players: NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer B - Barchart.com
Arrowhead Pharmaceuticals Hits New 52-Week High of $43.69 - Markets Mojo
Is Arrowhead Pharmaceuticals Inc. stock cheap at current valuationMarket Sentiment Report & Technical Pattern Alert System - newser.com
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockJuly 2025 Macro Moves & High Return Trade Opportunity Guides - newser.com
Will Arrowhead Pharmaceuticals Inc. stock benefit from upcoming earnings reportsMarket Risk Report & Reliable Price Breakout Signals - newser.com
What makes Arrowhead Pharmaceuticals Inc. (HDP1) stock appealing to growth investors2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock signals breakout potential2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Pinnacle Associates Ltd. Purchases 70,399 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How to build a dashboard for Arrowhead Pharmaceuticals Inc. stockJuly 2025 Action & Long-Term Growth Stock Strategies - newser.com
Targeted Drug Delivery Market Set to Witness Massive Growth - openPR.com
Is Arrowhead Pharmaceuticals Inc. showing signs of accumulation2025 Price Momentum & Risk Managed Trade Strategies - newser.com
Why analysts remain bullish on Arrowhead Pharmaceuticals Inc. stockWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
Can Arrowhead Pharmaceuticals Inc. stock hit analyst price targets2025 Pullback Review & Expert Curated Trade Ideas - newser.com
Can Arrowhead Pharmaceuticals Inc. stock reach $100 price targetEarnings Overview Report & Daily Technical Stock Forecast Reports - newser.com
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):